Pfizer to Sell Low-Cost Drugs to Poor Countries

    29 May 2022

    The drug company Pfizer will make all of its patented medicines available at a not-for-profit price to 45 of the poorest countries.

    The company announced the effort at the recent World Economic Forum in Davos, Switzerland. Pfizer is calling it "An Accord for a Healthier World." It said new medicines and vaccines would be added to the list at not-for-profit prices when they are launched.

    The drugs include COVID-19 treatment Paxlovid and breast cancer drug Ibrance, the drugmaker said on Wednesday.

    Pfizer's coronavirus disease (COVID-19) pill Paxlovid is packaged in Ascoli, Italy, in this undated image obtained by Reuters on Nov. 16, 2021.
    Pfizer's coronavirus disease (COVID-19) pill Paxlovid is packaged in Ascoli, Italy, in this undated image obtained by Reuters on Nov. 16, 2021.

    The Bill & Melinda Gates Foundation said it can take four to seven years or longer for new treatments to become available in poor countries. Sometimes they do not become available at all.

    Pfizer said its plan includes 23 patented medicines and vaccines that the company fully owns. The medicines treat infectious diseases, some cancers, and rare and inflammatory diseases. In addition to Paxlovid and Ibrance, the list includes pneumonia vaccine Prevnar 13, rheumatoid arthritis drug Xeljanz and cancer treatments Xalkori and Inlyta.

    The COVID-19 vaccine Comirnaty developed with the German company BioNTech is also on the list.

    Pfizer's Chief Executive Officer Albert Bourla said that all the medicines being made available should be of use. "But clearly the antiviral Paxlovid is going to be a very big deal for them - if they need it they can get it immediately," he said.

    The 27 low-income countries and 18 lower-income countries included in the deal cover most of Africa and much of Southeast Asia. Five countries - Rwanda, Ghana, Malawi, Senegal and Uganda - have already agreed to join.

    Malawi's President Lazarus Chakwera made a statement about the agreement. He said it will let the countries and the drugmaker share "the burden of costs and tasks in the production and delivery of supplies that will save millions of lives."

    Pfizer has been criticized for how it made its COVID-19 vaccine available. Some poor countries waited for months after the approval of the vaccine in rich countries.

    Bourla said the new agreement uses information learned during the release of the vaccine. He added that the lack of health systems in some countries made providing the vaccine to people who needed it difficult.

    To avoid that, Bourla said the agreement not only supplies the treatments, it will also help organize a system to administer them.

    I'm Anna Matteo.

    Michael Erman reported this story for Reuters News Agency. Anna Matteo adapted it for VOA Learning English.


    Words in This Story

    patented –adj. describing a product whose sales are protected by a patent: a document giving its owner the right to sell a product for an amount of time and which bars others from copying it without permission

    inflammatory –adj. causing tissue in the body to increase in size or become red and painful

    burden –n. a cost in money or effort

    delivery –n. the process of taking something where it is meant to go